119th Congress
H.R. 10094
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Val T. Hoyle(D-OR)
- Introduced
- Aug 13, 2026
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce
- Official text
- Introduced in House · Congress.gov page
Cosponsors (15)
Original cosponsors (7)
- Eleanor Holmes Norton (D-DC)
- Greg Casar (D-TX)
- Lloyd Doggett (D-TX)
- Mark Takano (D-CA)
- Melanie A. Stansbury (D-NM)
- Pramila Jayapal (D-WA)
- Rashida Tlaib (D-MI)
Added later (8)
- Jesús G. "Chuy" García (D-IL) · Aug 20, 2026
- Jill N. Tokuda (D-HI) · Aug 20, 2026
- Ro Khanna (D-CA) · Aug 20, 2026
- Steve Cohen (D-TN) · Aug 20, 2026
- Janice D. Schakowsky (D-IL) · Aug 27, 2026
- Seth Magaziner (D-RI) · Aug 31, 2026
- Rosa L. DeLauro (D-CT) · Sep 1, 2026
- Chellie Pingree (D-ME) · Oct 9, 2026
Summary
No Congressional Research Service summary yet. CRS usually publishes one a few weeks after a bill is introduced.
Official title: To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.
Latest action(Aug 13, 2026): Referred to the House Committee on Energy and Commerce.
Roll-call votes
No recorded votes on this bill.
Actions
- Aug 13, 2026 · House
Referred to the House Committee on Energy and Commerce. - Aug 13, 2026
Introduced in House